ConcertAI (an ASCO initiative)
About ConcertAI (an ASCO initiative)
ConcertAI is a leading healthcare AI company that leverages generative and predictive AI, real-world data (RWD), and clinical expertise to deliver practical intelligence for the treatment of oncology and other complex diseases. The company’s mission is to accelerate insights and outcomes for patients by providing research-ready data, AI technologies, and scientific expertise. They partner with biomedical innovators, healthcare providers, and medical societies to achieve this goal.
For physicians, ConcertAI offers solutions designed to enhance various aspects of patient care and clinical research, particularly within oncology. Through initiatives like CancerLinQ, which ConcertAI acquired from ASCO in December 2023, they provide oncology providers with ASCO-aligned quality solutions and analytic services. Their SmartLinQ™ application, for example, integrates ASCO Guidelines and can provide guideline-concordant care recommendations for individual patients, helping oncologists consider a complete set of treatment options. Additionally, ConcertAI’s platforms aim to simplify and accelerate clinical trial participation, reduce administrative burdens, and improve patient matching to complex clinical trial enrollment criteria through intelligent screening features like TriaLinQ™. They also offer advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT through TeraRecon.
Focus Areas
Business Intelligence
| Technology | CARAai™ platform (predictive and generative AI), cloud-native, AI operating system, multi-modal data integration |
What Physicians Need to Know
For physicians, ConcertAI's solutions, particularly through the CancerLinQ initiative and SmartLinQ platform, offer automated, ASCO Guideline-concordant care recommendations directly within existing EMR workflows (e.g., Epic). This can streamline decision-making and ensure adherence to the latest standards. The AI-powered clinical trial screening (TriaLinQ) can significantly reduce the burden on clinical trial staff, allowing for faster identification of eligible patients and potentially increasing patient access to trials. Furthermore, the TeraRecon Oncology Suite provides advanced AI-powered diagnostic tools to assist in screening, diagnosis, and treatment planning across the cancer care pathway. The focus on real-world data and AI aims to provide more informed care strategies and improve patient outcomes.
ConcertAI's SmartLinQ solutions work directly within the workflows of Epic and other EMRs. They also offer an open AI framework within their CARA AI platform, allowing scientists to embed and orchestrate third-party, first-party, or open-source AI algorithms. Collaborations with partners like NVIDIA further enhance their capabilities for large-scale AI applications and multi-modal data processing.
What the Web Says
ConcertAI, which acquired CancerLinQ from ASCO in December 2023, is a company focused on real-world data and AI technologies in oncology. CancerLinQ, originally developed by ASCO, is a learning health system that aggregates electronic health record data from oncology practices to improve quality of care and support research. While some employee reviews highlight good benefits and interesting work with medical data, there are significant concerns regarding management, work-life balance, and job security. Product reviews for ConcertAI's offerings, including the RWD360 platform and Patient360, emphasize their utility in providing comprehensive clinical data and insights for research and clinical decision-making.
Overall: MixedStrengths
- Good benefits (according to some employee reviews).
- Interesting work with medical data.
- CancerLinQ automates quality measure reporting, saving time for oncology practices.
- ConcertAI's AI-based clinical trial screening is significantly faster than traditional methods.
- Products like RWD360 and Patient360 offer comprehensive real-world data and insights for oncology research and care.
- CancerLinQ aims to close the gap between routine clinical care and clinical research, providing decision support and trial matching.
Limitations
- Poor management and leadership.
- Lack of work-life balance, with expectations of long hours.
- Issues with job security and advancement opportunities.
- Toxic culture and favoritism reported by some employees.
- Concerns among patients and providers about data privacy and sharing with pharmaceutical companies.
- Frequent changes in guidelines and lack of communication from management.
Based on reviews from: Indeed.com, Great Place To Worku00ae, Elion Health, PubMed, ConcertAI (Press Releases), Reddit, The Cancer Letter, UNC Lineberger Comprehensive Cancer Center, Capterra
Last updated: 2026-10-01
Videos
News, demos, and interviews about ConcertAI (an ASCO initiative).
Videos load interactively. If none appear, search YouTube for ConcertAI (an ASCO initiative) →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]